CSV April 3, 2023 through April 3, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NICARDIPINE	DEFINITION	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE INJECTION								NTL 90.0% to: NLT 90.0%
AMLODIPINE BESYLATE	*Assay*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In *Chromatographic system*: Change Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the standard deviation for replicate injections is not more than 2.0%. to: Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the relative standard deviation for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								replicate injections is not more than 2.0%.
ONDANSETRON INJECTION	*USP Reference standards* <11>	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride. AND In USP Ondansetron Related Compound C RS: Change 1,2,3,9-Tetrahy

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								d ro- 9-me thyl-4*H* -carbazol-4-one . to: 9-Methyl-1,2,3,9 -tet rahydr o-4*H* -carbazol-4-one . AND In USP Ondansetron Related Compound D RS: Change 1,2,3,9-Tetrahy dro-9-methyl-3- met hylene- 4*H* -carbazol-4-one . to: 9-Methyl-3-met hylene-1,2,3,9-t etra hydro-4*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-carbazol-4-one.
LORATADINE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In *Tier 1*/*Solution A* and *Tier 2*/*Solution B*: Change Tween 20 to: polysorbate 20
FULVESTRANT	CHEMICAL INFORMATION	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	Change 606.77 to: 606.78
ORPHENADRINE CITRATE EXTENDED-RELEASE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards* <11>	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Orphenadrine Related Compound B RS: Change *N*-Ethyl-*N*,*N*-dimethyl [2-2(methylbenzhydryloxy)ethyl]ammonium chloride; Also known as *N*-Ethyl-*N*,*N*-dimethyl-2-[phenyl(*o*-tolyl)methoxy]ethanaminium chloride.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *N*-Ethyl-*N*,*N*-dimethyl [2-(2-methylbenzhydryloxy)ethyl]ammonium chloride; also known as *N*-Ethyl-*N*,*N*-dimethyl-2-[phenyl(2-tolyl)methoxy]ethanaminium chloride.
WARFARIN SODIUM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Warfarin Related Compound A RS: Change 3-(*o*-Hydroxyphenyl)-5-phenyl-2-cyclohexen-1-one. to: 3-(2-Hydroxyphenyl)-5-phenyl-2-cyclohexen-1-one. AND Change 264.33 to: 264.32
AMLODIPINE	*Related*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BESYLATE	*compounds/Test 2*							*Chromatographic system*: Change Chromatograph the *Standard solution*, and record the peak responses as directed for *Procedure*: the standard deviation for replicate injections is not more than 10.0%. to: Chromatograph the *Standard solution*, and record the peak responses as directed for *Procedure*: the relative standard deviation for replicate injections is not more than 10.0%.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ONDANSETRON	*USP Reference standards <11>*	*USPNF 2021 ISSUE 1*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	Change USP Ondansetron RS USP Ondansetron Related Compound C RS 1,2,3,9-Tetrahydro-9-methyl-4*H*-carbazol-4-one. USP Ondansetron Related Compound D RS 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4*H*-carbazol-4-one. to: USP Ondansetron

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 9-Methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one. USP Ondansetron Related Compound D RS 9-Methyl-3-methylene-1,2,3,9-t

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								etra hydro-4*H* -carbazol-4-one .
CARBOPLATIN FOR INJECTION	IM PURITIES/*Limit of 1,1-Cyclobutanedicarboxylic Acid*	*USPNF 2021 ISSUE 1*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	In *Chromatographic system*/*Column*: Change 4.0-mm × 30-cm; packing L1 to: 3.9-mm × 30-cm; packing L1
CALCIUM SACCHARATE	ASSAY/ *Procedure*	*USPNF 2021 ISSUE 1*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	In *Analysis*: Change Result = {[(V_S ? V_B) × *N* × *F*]/*W*} × 100 to: Result = {[(V_S ? V_B) × *M* × *F*]/*W*} × 100 AND Change *N* = actual normality of the *Titrant* (mEq/mL)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								F = equivalency factor, 320.2 mg/mEq to: *M* = actual molarity of the *Titrant* (mmol/mL) *F* = equivalency factor, 320.26 mg/mmol
EXTENDED PHENYTOIN SODIUM CAPSULES	ASSAY/ *Procedure*	*Revision Bulletin (Official March 01, 2021)*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	In *Sample solution*: Change Nominally 0.6 mg/mL of phenytoin to: Nominally 0.6 mg/mL of phenytoin sodium AND In *Analysis*: Change C_U = nominal concentration of phenytoin in the *Sample solution* (mg/mL) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_U = nominal concentration of phenytoin sodium in the *Sample solution* (mg/mL)
CARBOPLATIN	IM PURITIES/*Limit of 1,1-Cyclobutanedicarboxylic Acid*	*USPNF 2021 ISSUE 1*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	In *Chromatographic system*/*Column*: Change 4.0-mm × 30-cm; packing L1 to: 3.9-mm × 30-cm; packing L1
SUCCINYLCHOLINE CHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	In USP Succinylmonocholine Chloride RS: Change Ethanaminium, 2-(carboxy-1-oxopropoxy)-*N*,*N*,*N*-trimethyl-, chloride. to: Ethanaminium, 2-(3-carboxy-1-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ox opro poxy)-*N*,*N*,*N* -trimethyl-, chloride; Also known as 2-[(3-Carboxypr op anoy l)oxy]-*N*,*N*,*N* -trimethylethan-1-aminium chloride.
ATORVASTATIN CALCIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	In USP Atorvastatin Related Compound C RS: Change $C_{66}H_{66}F_4N_4O_{10}$ to: $C_{66}H_{66}CaF_4N_4O_{10}$ AND In USP Atorvastatin Related Compound E RS: Change 1155.38 to: 1155.36

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EXTENDED PHENYTOIN SODIUM CAPSULES	IM PURITIES/*Organic Impurities*	*Revision Bulletin (Official March 01, 2021)*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	In both Calculations in *Analysis*: Change C_U = nominal concentration of phenytoin in the *Sample solution* (µg/mL) to: C_U = nominal concentration of phenytoin sodium in the *Sample solution* (µg/mL)
PRAZOSIN HYDROCHLORIDE	IM PURITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	In *Sensitivity solution*: Change 0.05 µg/mL of USP Prazosin Hydrochloride RS in *Mobile phase* from the *Standard solution* to: 0.5 µg/mL of USP Prazosin Hydrochloride RS in *Mobile*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phase from the *Standard solution*
CAPTOPRIL	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	In USP Captopril Disulfide RS: Change L-Proline, 1,1?-[dithiobis(2-methyl-1-oxo-3,1-propanediyl)] bis-[*S*-(*R**,*R**)]-. to: (2?*S*)-[(2*S*,2?*S*)-3,3?-Disulfanediylbis(2-methylpropanoyl)] di-L-proline.
ELEUTHERO ROOT AND RHIZOME DRY EXTRACT	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	Change USP Eleutheroside B RS ?-D-Glucopyranoside, 4-(3-hydroxy-1-propenyl)-2,6-dimethoxyphenyl. C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{17}H_{24}O_9$ 372.37 USP Eleutheroside E RS ?-D-Glucopyranoside, (tetrahydro-1*H*,3*H*-furo(3,4-c)furan-1,4-diyl)bis(2,6-dimethoxy-4,1-phenylene)bis-. $C_{34}H_{46}O_{18}$ 742.70 to: USP Eleutheroside B RS USP Eleutheroside E RS
DACARBAZINE FOR INJECTION	IMPURITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	Delete *Diluent*: 4.0 mg/mL of citric acid in water
ELEUTHERO ROOT AND RHIZOME	ADDITIONAL REQUIREMENTS/*USP Reference*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	Change USP Eleutheroside B RS

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Standards <11>							?-D-Glucopyranoside, 4-(3-hydroxy-1-propenyl)-2,6-dimethoxyphenyl. $C_{17}H_{24}O_9$ 372.37 USP Eleutheroside E RS ?-D-Glucopyranoside, (tetrahydro-1*H*,3*H*-furo(3,4-c)furan-1,4-diyl)bis(2,6-dimethoxy-4,1-phenylene)bis-. $C_{34}H_{46}O_{18}$ 742.70 to: USP Eleutheroside B RS USP Eleutheroside E RS
ESTROPIPATE CHEMICAL INFORMATION		*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	Change 436.56 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS	*Dissolution <711>*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	436.57 In *Test 2*: Change Determine the amount of isosorbide dinitrate ($C_6H_9NO_6$) dissolved by employing the following method. to: Determine the amount of isosorbide dinitrate ($C_6H_8N_2O_8$) dissolved by employing the following method.
APREPITANT CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	In *Test 1*/*Apparatus 2*: Change [Note—A suitable sinker is available from VanKel, www.chem.agilent.com,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								catalog number 12-3050. Proper placement of the Capsules is in the sinkers with the cap facing the fixed prong end.] to: [Note—A suitable sinker is available from www.agilent.com, catalog number 12-3050. Proper placement of the Capsules is in the sinkers with the cap facing the fixed prong end.]
ISOPROTERENOL HYDROCHLORIDE INJECTION	*Color and clarity*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	Change Using the Injection as the *Test solution*, proceed as directed for *Color and clarity* under *Isoproterenol*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Inhalation Solution. to: *Standard solution* —Transfer 2.0 mL of 0.100 N iodine VS to a 500-mL volumetric flask, dilute with water to volume, and mix. *Proce dure*—Visually examine a portion of the Injection (*Test solution*) in a suitable clear glass test tube against a white background: it is not pinkish and it contains no precipitate. If any yellow color is observed in the *Test solution*, concomitantly

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								determine the absorbances of the *Test solution* and the *Standard solution* in 1-cm cells with a suitable spectrophotometer set at 460 nm: the absorbance of the *Test solution* does not exceed that of the *Standard solution*.
ELEUTHEROROOT AND RHIZOME POWDER	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	Change USP Eleutheroside B RS ?-D-Glucopyranoside, 4-(3-hydroxy-1-propenyl)-2,6-dimethoxyphenyl. $C_{17}H_{24}O_9$ 372.37 USP Eleutheroside E RS ?-D-Glucopyran

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oside, (tetrahydro-1*H*,3*H*-furo(3,4-c)furan-1,4-diyl)bis(2,6-dimethoxy-4,1-phenylene)bis-. $C_{34}H_{46}O_{18}$ 742.70 to: USP Eleutheroside B RS USP Eleutheroside E RS
DACARBAZINE	IMPURITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	In *System suitability/Suitability requirements/Signal-to-noise ratio*: Change NTL 10 to: NLT 10
CARBOMER INTERPOLYMER	IMPURITIES/*Limit of Benzene*	*USPNF 2021 ISSUE 2*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	In *Analysis*: Change W_U = weight of Carbomer Interpolymer in the *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution (mg) to: W_U = weight of Carbomer Interpolymer in the *Sample solution* (?g)
CEFTIOFUR HYDROCHLORIDE	IMPURITIES/*Low Molecular Weight Impurities*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	In *Analysis*: Change Result = $\{r_U/[r_S + (?r_U/F)]\} \times (1/F) \times 100$ to: Result = $\{r_U/[r_S + ?(r_U/F)]\} \times (1/F) \times 100$
DOXAZOSIN MESYLATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	29-Oct-2021	1-Nov-2021	*NA*	*NA*	In USP Doxazosin Related Compound D RS: Change 1,4-Benzodioxane-2-carboxylic acid. $C_9H_8O_5$ 196.16 to: 1,4-Benzodioxane-2-carboxylic acid. $C_9H_8O_4$ 180.16
ECHOTHIOPH	SPECIFIC	*USPNF2021*	Online	29-Oct-2021	1-Nov-2021	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATE IODIDE FOR OPHTHALMIC SOLUTION	TESTS/ *Water/Analysis*	*Issue 1*						Result = [(*C*/*V*)/*W*] × 100 to: Result = [(*C* × *V*)/*W*] × 100
TIAGABINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	29-Oct-2021	1-Nov-2021	*NA*	*NA*	In USP Tiagabine Hydrochloride RS: Delete [NOTE—Available in monohydrate form.]
DIMENHYDRINATE ORAL SOLUTION	*Content of 8-chlorotheophylline*	*USPNF 2021 ISSUE 1*	Online	29-Oct-2021	1-Nov-2021	*NA*	*NA*	Change *Ammonium bicarbonate solution, Diluent, Solution A, Solution B, Mobile phase, Internal standard solution,* and *Chromatographic system* —Proceed as directed in the *Assay* under *Dimenhydrinate*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Tablets. to: *Ammonium bicarbonate solution* —Dissolve 4 g of ammonium bicarbonate in 250 mL of water. *Diluent* —Dissolve 4 g of ammonium bicarbonate in 200 mL of water. Add 50 mL of methanol, and mix. *Solution A*—Dissolve 0.8 g of ammonium bicarbonate in 800 mL of water. Add 200 mL of methanol, filter, and degas. *Solution B*—Dissolve 0.8 g of ammonium bicarbonate in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								150 mL of water. Add 850 mL of methanol, filter, and degas. *Mobile phase*—Use variable mixtures of *Solution A* and *Solution B* as directed for *Chromatographic system*. Make adjustments if necessary (see *System Suitability* under *Chromatography* ?621?). *Internal standard solution*—Prepare a solution in methanol containing 2.0 mg of 2-hydroxy benzyl alcohol per mL. AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change *Standard solution* —Prepare as directed for *Standard preparation* in the *Assay* under *Dimenhydrinate Tablets*. to: *Standard solution* —Accurately weigh about 50 mg of USP Dimenhydrinate RS, add about 5 mL of *Ammonium bicarbonate solution* and 20.0 mL of *Internal standard solution*, and mix. To 1 mL of this solution add about 9 mL of *Diluent*, and mix.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Add *Chromatographic system* (see *Chromatography* ?621?)—The liquid chromatograph is equipped with a 229-nm detector and a 4.6-mm × 25-cm column that contains packing L7. The flow rate is about 1.5 mL per minute. The chromatograph is programmed as follows. Time (minutes), 0, 0–7.0, 7.0–7.1, 7.1–15, 15–15.1, 15.1–22.0 Solution A (%), 100, 100, 100?0, 0, 0?100, 100

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Solution B (%), 0, 0, 0?100, 100, 100?0, 0 Elution, equilibration, isocratic, linear gradient, isocratic, linear gradient, isocratic Chromatograph the *Standard solution*, and record the peak areas as directed for *Procedure*: the relative retention times are about 0.3 for 8-chlorotheophylline, 0.5 for the internal standard, and 1.0 for diphenhydramine; the resolution, *R*, between 8-chlorotheophylline and the internal

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								standard is not less than 4.5; and the relative standard deviation for replicate injections is not more than 2.0%.
DOXAZOSIN MESYLATE	IM PUR ITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	29-Oct-2021	1-Nov-2021	*NA*	*NA*	In *Table 2*: Change Doxazosin related compound D[g] 0.83, 196.16, 196.16, 0.25 to: Doxazosin related compound D[g] 0.83, 180.16, 180.16, 0.25
ARTICLES OF BOTANICAL ORIGIN	PESTICIDE RESIDUE ANA LYSIS/*Limits*	*USPNF2021 Issue 1*	Online	29-Oct-2021	1-Nov-2021	*NA*	*NA*	In *Qualitative and Quantitative Analysis of Pesticide Residues*: Change [Note—Current version

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Document No. SANTE/11813/2017, https://ec.europa.eu/food/sites/food/files/plant/docs/pesticides_mrl_guidelines_wrkdoc_2017-11813.pdf] to: [Note—Current version Document No. SANTE/12682/2019, https://ec.europa.eu/food/system/files/2020-01/pesticides_mrl_guidelines_wrkdoc_2019-12682.pdf]
ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	29-Oct-2021	1-Nov-2021	*NA*	*NA*	In *Analysis*: Change r_S = peak response of alfuzosin from the *Sample solution* to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								r_S = peak response of alfuzosin from the *Standard solution*
DIMENHYDRINATE ORAL SOLUTION	*Assay*	*USPNF 2021 Issue 1*	Online	29-Oct-2021	1-Nov-2021	*NA*	*NA*	Change *Ammonium bicarbonate solution, Diluent, Solution A, Solution B, Mobile phase, Internal standard solution, Standard preparation,* and *Chromatographic system* —Proceed as directed in the *Assay* under *Dimenhydrinate Tablets*. to: *Ammonium bicarbonate solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								—Dissolve 4 g of ammonium bicarbonate in 250 mL of water. *Diluent* —Dissolve 4 g of ammonium bicarbonate in 200 mL of water. Add 50 mL of methanol, and mix. *Solution A*—Dissolve 0.8 g of ammonium bicarbonate in 800 mL of water. Add 200 mL of methanol, filter, and degas. *Solution B*—Dissolve 0.8 g of ammonium bicarbonate in 150 mL of water. Add 850 mL of methanol, filter, and degas.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Mobile phase—Use variable mixtures of *Solution A* and *Solution B* as directed for *Chromatographic system*. Make adjustments if necessary (see *System Suitability* under *Chromatography* ?621?). *Internal standard solution*—Prepare a solution in methanol containing 2.0 mg of 2-hydroxy benzyl alcohol per mL. *Standard preparation*—Accurately weigh about 50 mg of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Dimenhydrinate RS, add about 5 mL of *Ammonium bicarbonate solution* and 20.0 mL of *Internal standard solution*, and mix. To 1 mL of this solution add about 9 mL of *Diluent*, and mix. AND Add *Chromatographic system* (see *Chromatography* ?621?)—The liquid chromatograph is equipped with a 229-nm detector and a 4.6-mm × 25-cm column that contains packing L7. The flow rate is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								about 1.5 mL per minute. The chromatograph is programmed as follows. Time (minutes), 0, 0–7.0, 7.0–7.1, 7.1–15, 15–15.1, 15.1–22.0 Solution A (%), 100, 100, 100?0, 0, 0?100, 100 Solution B (%), 0, 0, 0?100, 100, 100?0, 0 Elution, equilibration, isocratic, linear gradient, isocratic, linear gradient, isocratic Chromatograph the *Standard preparation*, and record the peak areas as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directed for *Procedure*: the relative retention times are about 0.3 for 8-chlorotheophylline, 0.5 for the internal standard, and 1.0 for diphenhydramine; the resolution, *R*, between 8-chlorotheophylline and the internal standard is not less than 4.5; and the relative standard deviation for replicate injections is not more than 2.0%. AND Change *Procedure*—Proceed as directed for *Procedure* in the *Assay* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Dimenhydrinate Tablets. to: *Proce dure* —Separately inject equal volumes (about 10 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the areas for the major peaks.
PAROXETINE HYDROCHLORIDE	CHEMICAL INFORMATION	*Interim Revision Announcement (Official May 01, 2021)*	Online	29-Oct-2021	1-Nov-2021	*NA*	*NA*	Change (?)-(3*S*,4*R*)-4-(*p*-Fluorophenyl)-3-[(3,4-methylenedioxy)phenoxy]methyl]piperidine hydrochloride; to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(?)-(3*S*,4*R*)-4-(*p*-Fluorophenyl)-3-[[(3,4-methylenedioxy)phenoxy]methyl]piperidine hydrochloride;
SACCHARIN	SPECIFIC TESTS/*Readily Carbonizable Substances Test <271>*	*USPNF 2021 ISSUE 1*	Online	24-Sep-2021	1-Oct-2021	*NA*	*NA*	In *Matching fluid A*: Change Cobaltous chloride CS, ferric chloride TS, cupric sulfate CS, and water (0.1:0.4:0.1:4.4) to: Cobaltous chloride CS, ferric chloride CS, cupric sulfate CS, and water (0.1:0.4:0.1:4.4)
GLYBURIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	24-Sep-2021	1-Oct-2021	*NA*	*NA*	In USP Glyburide Related Compound A RS: Change 4-[2-(5-Chloro-2

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-methoxybenzamido)ethyl]benzenesulfonamide. to: 4-[2-(5-Chloro-2-methoxybenzamido)ethyl]benzenesulfonamide.
ACETAMINOPHEN TABLETS	IMPURITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	24-Sep-2021	1-Oct-2021	*NA*	*NA*	In *Chromatographic system*/*Detector*: Change UV 272 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm. to: UV 272 nm
ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—GENERAL	1. OVERVIEW: GENERAL CHAPTERS BASED ON SCATTERING PHENOMENA	*USPNF 2021 ISSUE 1*	Online	24-Sep-2021	1-Oct-2021	*NA*	*NA*	In *Table 1*: Change ?1430.6?[a] to: ?1430.6? AND Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								?1430.7?[a] to: ?1430.7? AND Delete footnote a
LIGHT OBSCURATION METHOD FOR THE DETERMINATION OF SUBVISIBLE PARTICULATE MATTER	AP PENDIX/*Particle Count Accuracy Manual Method Test for MWHC Instruments*	*USPNF 2021 ISSUE 1*	Online	24-Sep-2021	1-Oct-2021	*NA*	*NA*	In *Overview*: Change The test is also sensitive to size accuracy at 15 ?m, since small errors in size will translate into large errors in count at the midpoint of the PS distribution. to: The test is also sensitive to size accuracy at 15 ?m, since small errors in size will translate into large errors in count at the midpoint of the particle size distribution.
HYDROXYETH IM		*USPNF 2021*	Online	24-Sep-2021	1-Oct-2021	*NA*	*NA*	In *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
YL CELLULOSE	PUR ITIES/ *Aldehydes*	*ISSUE 1*						Change To 2.0 mL of the *Sample solution*, add 5.0 mL of a 4-g/L solution of methylbenzothiazolone hydrazone hydrochloride to an 80% (v/v) solution of glacial acetic acid in water. to: To 2.0 mL of the *Sample solution*, add 5.0 mL of a 4-g/L solution of methylbenzothiazolone hydrazone hydrochloride in an 80% (v/v) solution of glacial acetic acid in water.
OFLOXACIN	CHEMICAL INFORMATION	*USPNF 2021 ISSUE 1*	Online	24-Sep-2021	1-Oct-2021	*NA*	*NA*	Change (±)-9-Fluoro-2,3-dihydro-3-meth

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								yl-10-(4-methyl-l -piperazinyl)-7-o xo-7*H* -p yrido [1,2,3-*de*]-1,4-benzoxazi ne-6-carboxylic acid to: (±)-9-Fluoro-2, 3-dihydro-3-met hyl-10-(4-methyl -1-piperazinyl)-7 -oxo-7*H* -p yrido [1,2,3-*de*]-1,4-benzoxazi ne-6-carboxylic acid
ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA-GENERAL	2. INTRODUCTION	*USPNF 2021 ISSUE 1*	Online	24-Sep-2021	1-Oct-2021	*NA*	*NA*	In paragraph five: Change *Determination of Zeta Potential by Electrophoretic Light Scattering* ?432?[1] to: *Determination*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of Zeta Potential by Electrophoretic Light Scattering ?432? AND In footnote 1: Change This chapter will appear in a future *Pharmacopeial Forum* (*PF*) issue. to: This chapter appeared in issue 46(3) of the *Pharmacopeial Forum* (*PF*).
PYRANTEL PAMOATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 2*	Online	24-Sep-2021	1-Oct-2021	*NA*	*NA*	In USP Pyrantel Related Compound A RS: Change (*Z*)-1-Methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$C_{34}H_{30}N_2O_6S$ 594.69 to: (*Z*)-1-Methyl-2-[2-(2-thiophenyl)vinyl]-1,4,5,6-tetrahydropyrimidine 4,4'-methylene bis[3-hydroxy-2-naphthoate] (1:1). $C_{11}H_{14}N_2S \cdot C_{23}H_{16}O_6$ 594.68
RIFABUTIN	IMPURITIES/*Organic Impurities, Procedure 2*	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	In *Sample solution*: Change 1 mg/mL of USP Rifabutin RS prepared as follows. to: 1 mg/mL of Rifabutin prepared as follows.
SPECTROSCOPIC IDENTIFICATION TESTS	EQUIVALENT/ALTERNATIVE TESTS	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	Change (see *Mass Spectrometry* ?736?, *Nuclear*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Magnetic Resonance Spectroscopy ?761?, ?854?, ?857?, ?941?, *Near-Infrared Spectroscopy—Theory and Practice* ?1856?, and ?858?. to: (see *Mass Spectrometry* ?736?, *Nuclear Magnetic Resonance Spectroscopy* ?761?, ?854?, ?856?, ?857?, ?858?, and ?941?).
QUETIAPINE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*/*System Suitability*	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	In *Resolution*: Change NLT 2.0 between the quetiapine desthoxy and quetiapine peaks to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								NLT 2.0 between the quetiapine desethoxy and quetiapine peaks

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- …
- Next page Next ›
- Last page Last »